Panos Zanos

1 month ago | biorxiv.org | Andrea Georgiou |Panos Zanos |Anna Onisiforou

AbstractAlzheimer′s disease (AD) and Diabetes Mellitus Type II (DM2) share overlapping pathological mechanisms, with DM2 increasing AD risk. Disease-modifying therapies (DMTs) for DM2, including Metformin and Semaglutide, have been explored for neuroprotection, yet their efficacy in AD remains unclear.

Jan 5, 2025 | mdpi.com | Panos Zanos

1. IntroductionAlzheimer’s Disease (AD) is a progressive and chronic neurodegenerative disease (ND) affecting the central nervous system (CNS), marked primarily by memory loss and cognitive deterioration []. Conventional treatments offer symptomatic relief, but no pharmacotherapies have yet been able to halt or reverse its progression []. AD is the most common type of dementia among older adults, impacting approximately 55 million individuals globally [].

Jul 15, 2024 | pharmrev.aspetjournals.org | Panos Zanos |Ruin Moaddel |Patrick Morris |Lace M. Riggs

AbstractKetamine, a racemic mixture consisting of (S)- and (R)-ketamine, has been in clinical use since 1970. Although best characterized for its dissociative anesthetic properties, ketamine also exerts analgesic, anti-inflammatory, and antidepressant actions. We provide a comprehensive review of these therapeutic uses, emphasizing drug dose, route of administration, and the time course of these effects.

Jul 3, 2024 | sciencedirect.com | A. Auerbach |Panos Zanos |Todd Gould |Yoshifumi Okochi

Despite the importance of speed in synaptic transmission, in many synapses, neurotransmitters bind to their receptors at rates that appear to be slower than the diffusion limit. This assessment is generally based on a comparison with the Smoluchowski limit rather than an independent experimental analysis. In many synapses, miniature excitatory postsynaptic currents (mEPSCs) are controlled by the interplay between binding to receptors and diffusion of the neurotransmitter out of the synaptic cleft.